In Vitro a Fertile Niche for Lenders
By Jessica Silver-Greenberg,
Wall Street Journal
| 02. 24. 2012
Julie Barth's prayers were answered when a doctor in Crystal Lake, Ill., told her in vitro fertilization might get her pregnant.
But he didn't stop there, referring her to a "fertility finance" company that lent her $5,000 at an interest rate of 7.99% to help cover the $24,000 procedure. Her daughter, Olivia, was born about a year later.
"You can't put a price on a smile like that," says Ms. Barth, 32 years old. She hopes to pay off her loan from Springstone Financial LLC, based in Southborough, Mass., by her daughter's third birthday in 2014.
At a time when many traditional lenders are struggling, companies that join forces with doctors to make loans for in vitro fertilization, egg harvesting and other fertility treatments say their business is thriving.
One reason: Fertility-finance companies are getting a boost from the banking industry's retrenchment. For example, credit has become tight for home-equity loans and credit cards, two ways couples often have paid for fertility treatments that often top $20,000. Mike Gilroy, Springstone's president, says business is robust because "if the time is...
Related Articles
By Tory Shepherd, The Guardian | 07.17.2026
Over eight years, Ethan and his wife went through nine rounds of IVF in Melbourne.
They travelled to Spain for two more, without success.
“I thought maybe the universe had decided we’re not supposed to have kids,” says Ethan, who...
By Oscar Lopez, The Guardian | 07.19.2026
Diogo Amaro met his future husband, Loup, in Paris and from the first date, he made one thing clear: he wanted to have children.
“Right off the bat, I was like: ‘If I’m going to be in a relationship with...
By Risa Cromer, The Conversation | 07.17.2026
Media coverage of recent developments in embryo gene editing might seem to suggest that gene-edited babies are close to becoming a reality. As tech billionaires eager to profit off of techno-eugenics invest in “designer baby” technologies, attempts to normalize heritable genome editing – which remains unsafe and raises significant ethical and societal concerns – are especially dangerous. It’s worth taking a closer look at these developments and what they mean, in a way that pushes back on narratives normalizing the...